1887

Chapter 110 : Monitoring of Immunologic Therapies

Author: Theresa L. Whiteside1
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: University of Pittsburgh Cancer Institute, Research Pavilion at the Hillman Cancer Center, 5117 Centre Ave. Suite 1.27, Pittsburgh, PA 15213
Content Type: Reference
Publication Year: 2016

Category: Immunology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Monitoring of Immunologic Therapies, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH110-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH110-2.gif

Abstract:

Immunologic therapies are becoming increasingly widely utilized. The current interest in these therapies is due to considerable successes in treatment outcomes in a broad spectrum of human diseases targeted for biotherapy, including inheritable or acquired immunodeficiencies, autoimmune diseases, cancer, and persistent infections. Many new biologic agents are available for immune therapy, and antibodies, cytokines, activated or genetically modified immune cells, vaccines, and other immunomodulatory drugs are frequently used either as monotherapies or in combination with conventional therapies such as chemotherapy, radiation, surgery, and even behavior-modifying therapies. In cancer, biotherapies are expected to restore dysfunctional antitumor immune responses, activate immune cells, and help immune cells to reacquire normal homeostasis. In addition, tumors resistant to standard therapies are often sensitive to immune interventions, and this offers a promise of combinatorial therapies to overcome drug resistance.

Citation: Whiteside T. 2016. Monitoring of Immunologic Therapies, p 1036-1050. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch110
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818722.ch110
1. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML . 2011. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 17 : 3064– 3076.[CrossRef].[PubMed]
2. Matzinger P . 2002. The danger model: a renewed sense of self. Science 296 : 301– 305.[CrossRef].[PubMed]
3. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H . 2008. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27 : 218– 224.[CrossRef].[PubMed]
4. Whiteside TL . 2010. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 10 : 1019– 1035.[CrossRef].[PubMed]
5. Postow MA, Harding J, Wolchok JD . 2012. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 18 : 153– 159.[PubMed]
6. Brahmer JR . 2012. PD-1-targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol 10 : 674– 675.[PubMed]
7. Mellman I, Coukos G, Dranoff G . 2011. Cancer immunotherapy comes of age. Nature 480 : 480– 489.[CrossRef].[PubMed]
8. Restifo NP, Dudley ME, Rosenberg SA . 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12 : 269– 281.[CrossRef].[PubMed]
9. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS . 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 : 1020– 1030.[CrossRef].[PubMed]
10. Herberman RB . 1985. Design of clinical trials with biological response modifiers. Cancer Treat Rep 69 : 1161– 1164.[PubMed]
11. Kennedy-Nasser AA, Ku S, Castillo-Caro P, Hazrat Y, Wu MF, Liu H, Melenhorst J, Barrett AJ, Ito S, Foster A, Savoldo B, Yvon E, Carrum G, Ramos CA, Krance RA, Leung K, Heslop HE, Brenner MK, Bollard CM . 2014. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 20 : 2215– 2225.[CrossRef].[PubMed]
12. Malek TR, Pugliese A . 2011. Low-dose IL-2 as a therapeutic agent for tolerance induction. Immunotherapy 3 : 1281– 1284.[CrossRef].[PubMed]
13. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D . 2011. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365 : 2067– 2077.[CrossRef].[PubMed]
14. Hank JA, Kohler PC, Weil-Hillman G, Rosenthal N, Moore KH, Storer B, Minkoff D, Bradshaw J, Bechhofer R, Sondel PM . 1988. In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2. Cancer Res 48 : 1965– 1971.[PubMed]
15. Amado IF, Berges J, Luther RJ, Mailhé MP, Garcia S, Bandeira A, Weaver C, Liston A, Freitas AA . 2013. IL-2 coordinates IL-2-producing and regulatory T cell interplay. J Exp Med 210 : 2707– 2720.[CrossRef].[PubMed]
16. Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM . 1993. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. J Immunother Emphasis Tumor Immunol 13 : 43– 48.[PubMed].[CrossRef]
17. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM . 2001. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 19 : 2576– 2582.[PubMed].[CrossRef]
18. Rosenthal R, Viehl CT, Guller U, Weber WP, Adamina M, Spagnoli GC, Heberer M, Zuber M . 2008. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. J Am Coll Surg 207 : 95– 105.[CrossRef].[PubMed]
19. Xu LW, Chow KK, Lim M, Li G . 2014. Current vaccine trials in glioblastoma: a review. J Immunol Res 2014 : 796856. doi:10.1155/2014/796856.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1155/2014/796856
20. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE . 1989. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210 : 474– 484, discussion 484–485.[PubMed].[CrossRef]
21. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J . 1993. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91 : 123– 132.[CrossRef].[PubMed]
22. Whiteside TL . 2000. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin Diagn Lab Immunol 7 : 327– 332.[PubMed].[CrossRef]
23. Allegretta M, Atkins MB, Dempsey RA, Bradley EC, Konrad MW, Childs A, Wolfe SN, Mier JW . 1986. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol 6 : 481– 490.[PubMed].[CrossRef]
24. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M . 1999. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17 : 2889– 2895.[PubMed]
25. Manjili MH, Najarian K, Wang XY . 2012. Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol 8 : 703– 711.[CrossRef].[PubMed]
26. Whiteside TL . 2002. Cytokine assays. Biotechniques 33( Suppl) : 4– 8, 10, 12–15.
27. Elder EM, Whiteside TL, . 1992. Processing of tumors for vaccine and/or tumor-infiltrating lymphocytes, p 817– 819. In Friedman H, Rose NR, deMacario EC, Fahey JL, Friedman H, Penn GM (ed), Manual of Clinical Laboratory Immunology, 4th ed. American Society for Microbiology, Washington, DC.
28. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL . 2004. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10 : 3755– 3762.[CrossRef].[PubMed]
29. Perisanidis C, Kornek G, Pöschl PW, Holzinger D, Pirklbauer K, Schopper C, Ewers R . 2013. High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med Oncol 30 : 334 doi:10.1007/s12032-012-0334-5.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1007/s12032-012-0334-5
30. Whiteside TL, Stanson J, Shurin MR, Ferrone S . 2004. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 173 : 1526– 1534.[PubMed].[CrossRef]
31. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM . 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 : 94– 96.[PubMed].[CrossRef]
32. Schaefer C, Butterfield LH, Lee S, Kim GG, Visus C, Albers A, Kirkwood JM, Whiteside TL . 2012. Function but not phenotype of melanoma peptide-specific CD8 + T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer 131 : 874– 884.[CrossRef].[PubMed]
33. Freer G, Rindi L . 2013. Intracellular cytokine detection by fluorescence-activated flow cytometry: basic principles and recent advances. Methods 61 : 30– 38.[CrossRef].[PubMed]
34. Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaitero A, Ferris RL, Johnson JT, Whiteside TL . 2013. The immune signature of CD8 +CCR7 + T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res 19 : 889– 899.[CrossRef].[PubMed]
35. Boniface JD, Poschke I, Mao Y, Kiessling R . 2012. Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 131 : 129– 139.[CrossRef].[PubMed]
36. Whiteside TL . 2010. Immune responses to malignancies. J Allergy Clin Immunol 125( Suppl 2) : S272– S283.[CrossRef].[PubMed]
37. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F . 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 : 1960– 1964.[CrossRef].[PubMed]
38. Fridman WH, Galon J, Pagès F, Tartour E, Sautès-Fridman C, Kroemer G . 2011. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71 : 5601– 5605.[CrossRef].[PubMed]
39. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA . 2012. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10 : 205. doi:10.1186/1479-5876-10-205.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1186/1479-5876-10-205
40. Whiteside TL, Ferrone S . 2012. For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res 18 : 2417– 2419.[CrossRef].[PubMed]
41. Givan AL, Fisher JL, Waugh M, Ernstoff MS, Wallace PK . 1999. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 230 : 99– 112.[PubMed].[CrossRef]
42. Calarota SA, Baldanti F . 2013. Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays. Clin Dev Immunol 2013 : 637649 doi:10.1155/2013/637649.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1155/2013/637649
43. Asai T, Storkus WJ, Whiteside TL . 2000. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 7 : 145– 154.[PubMed]
44. Lehmann PV, Zhang W . 2012. Unique strengths of ELISPOT for T cell diagnostics. Methods Mol Biol 792 : 3– 23.[CrossRef].[PubMed]
45. Lucey DR, Clerici M, Shearer GM . 1996. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9 : 532– 562.[PubMed]
46. Lippitz BE . 2013. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14 : e218– e228.[CrossRef].[PubMed]
47. Butterfield LH, Potter DM, Kirkwood JM . 2011. Multiplex serum biomarker assessments: technical and biostatistical issues. J Transl Med 9 : 173. doi:10.1186/1479-5876-9-173.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1186/1479-5876-9-173
48. Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, Parslow TG . 1994. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 264 : 1596– 1599.[PubMed].[CrossRef]
49. Whiteside TL . 2012. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22 : 327– 334.[CrossRef].[PubMed]
50. Schuler PJ, Harasymczuk M, Schilling B, Saze Z, Strauss L, Lang S, Johnson JT, Whiteside TL . 2013. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 19 : 6585– 6596.[CrossRef].[PubMed]
51. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V . 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222 : 162– 179.[CrossRef].[PubMed]
52. Greten TF, Manns MP, Korangy F . 2011. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11 : 802– 807.[CrossRef].[PubMed]
53. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S . 2012. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 61 : 1155– 1167.[CrossRef].[PubMed]
54. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL . 2012. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 381 : 14– 22.[CrossRef].[PubMed]
55. Hoos A, Janetzki S, Britten CM . 2012. Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. Oncoimmunology 1 : 1457– 1459.[CrossRef].[PubMed]
56. Boniface JD, Poschke I, Mao Y, Kiessling R . 2012. Tumor-dependent down-regulation of the zeta-chain in T cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 131 : 129– 139.[CrossRef].[PubMed]

Tables

Monitoring of Immunologic Therapies
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555818722.ch110-1,webId=/content/author/10.1128/9781555818722.ch110-1,properties={foaf_givenname=Theresa L., foaf_name=Theresa L. Whiteside, foaf_surname=Whiteside, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555818722.ch110-aff1]]}]]
Citation: Whiteside T. 2016. Monitoring of Immunologic Therapies, p 1036-1050. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch110
/content/10.1128/9781555818722.ch110.ch110tab1
TABLE 1

Immunologic assays currently available for monitoring of phase I/II clinical trials with biologic agents

Generic image for table
TABLE 1

Immunologic assays currently available for monitoring of phase I/II clinical trials with biologic agents

Citation: Whiteside T. 2016. Monitoring of Immunologic Therapies, p 1036-1050. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch110

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error